JP
JAZZ
HealthcareJazz Pharmaceuticals
Price Chart
Loading...
Market Data
Revenue TTMXBRL
—
Net IncomeXBRL
—
Gross MarginXBRL
—
EPS (Diluted)XBRL
—
No analysis generated yet. Run the pipeline for this company.
AI-extracted key facts from press releases and SEC filings. Significance 1–10.
8
EarningsBullishPR NewswireMay 6, 2026
Jazz Pharmaceuticals Q1 revenue $1.1B +19% YoY, Zanidatamab granted Priority Review
- ▸Total revenue $1.1 billion, up 19% year-over-year
- ▸Zanidatamab HER2+ 1L GEA sBLA granted Priority Review; PDUFA date August 25, 2026
- ▸Xywav revenues grew 18% YoY with 425 net patient additions
- ▸Epidiolex revenues increased 15% year-over-year
8
EarningsBullishPR NewswireMay 6, 2026
Jazz Pharmaceuticals Q1 revenue $1.1B +19% YoY, Zanidatamab granted Priority Review
- ▸Total revenue $1.1 billion, up 19% year-over-year
- ▸Zanidatamab HER2+ 1L GEA sBLA granted Priority Review; PDUFA date August 25, 2026
- ▸Xywav revenues grew 18% YoY with 425 net patient additions
- ▸Epidiolex revenues increased 15% year-over-year